Date: 2016-08-10
Type of information: Licensing agreement
Compound: macrocycle molecules addressing biological targets selected by Gilead
Company: Gilead Sciences (USA - CA) Polyphor (Switzerland)
Therapeutic area: undisclosed
Type agreement: licensing collaboration
Action mechanism:
Disease: undisclosed
Details: * On August 10, 2016, Polyphor announced the signing of a collaboration and license agreement with Gilead Sciences. The collaboration aims to identify and optimize macrocycle molecules addressing biological targets selected by Gilead. In the initial phase of the collaboration Polyphor will apply its entire macrocycle platform consisting of nonpeptidic macrocyles (MacroFinder®), peptidic macrocycles (PEMfinder®, protein-epitope mimetics) and phage display of PEM-like molecules (PEMphage®) to generate tractable macrocycle hit
families for further optimization.
Financial terms: Under the terms of the Agreement, Polyphor will receive an upfront payment and research funding, and will be eligible for further milestone payments.
Latest news:
